Wafik Zaky1, Shekhar S Patil2, Minjeong Park3, Diane Liu3, Wei-Lien Wang4,5, Khalida M Wani5, Susana Calle6, Leena Ketonen6, Soumen Khatua7. 1. Department of Pediatric Patient Care, UT MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 87, Houston, TX, 77030, USA. 2. Department of Internal Medicine, McGovern Medical School, UT Health Science Center, 7440 Cambridge Street, Houston, TX, 77054, USA. 3. Department of Biostatistics, UT MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. 4. Department of Pathology, UT MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. 5. Department of Translational Molecular Pathology, UT MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. 6. Department of Diagnostic Radiology, UT MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. 7. Department of Pediatric Patient Care, UT MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 87, Houston, TX, 77030, USA. skhatua@mdanderson.org.
Abstract
BACKGROUND: Ganglioglioma (GG) is a rare mixed glial-neuronal neoplasm accounting for 0.5-5% of all pediatric central nervous system (CNS) tumors. Rarity of this tumor has precluded defining robust treatment guidelines. This retrospective study evaluates the prognostic factors and outcomes of this rare neoplasm. PATIENTS AND METHODS: Retrospective analysis of 55 patients with GG was conducted to describe clinical findings, and outcomes. Kaplan-Meier survival and Cox-regression analyses were performed to assess the overall survival (OS) and progression-free survival (PFS). RESULTS: The mean age at diagnosis was 11.8 years (range 1-21 years) with a median follow-up period of 9.5 years. 53 patients (92.7%) had low grade GG and 2 patients had anaplastic GG. 25 patients had tumor progression, whose median PFS was 12 years. Six patients with low grade GG progressed to a higher grade, with median survival of 9.1 month after transformation. The 5 and 10 year PFS were 65 and 57%, respectively. The 5 and 10 year OS was 96 and 86% respectively. 8 of the 19 (42%) samples tested demonstrated positivity for the BRAF V600E mutation. Multivariate Cox regression analyses showed location and extent of resection were significant factors for PFS and presence of metastatsis attained significance for OS. CONCLUSION: This is the one of the largest retrospective study of pediatric GG. Identifying clinical variables, which could stratify these tumors into low- and high-risk groups might help to profile a risk-based therapeutic strategy. Collaborative multiinstitutional prospective studies are warranted to delineate treatment consensus and investigate prognostic factors.
BACKGROUND: Ganglioglioma (GG) is a rare mixed glial-neuronal neoplasm accounting for 0.5-5% of all pediatric central nervous system (CNS) tumors. Rarity of this tumor has precluded defining robust treatment guidelines. This retrospective study evaluates the prognostic factors and outcomes of this rare neoplasm. PATIENTS AND METHODS: Retrospective analysis of 55 patients with GG was conducted to describe clinical findings, and outcomes. Kaplan-Meier survival and Cox-regression analyses were performed to assess the overall survival (OS) and progression-free survival (PFS). RESULTS: The mean age at diagnosis was 11.8 years (range 1-21 years) with a median follow-up period of 9.5 years. 53 patients (92.7%) had low grade GG and 2 patients had anaplastic GG. 25 patients had tumor progression, whose median PFS was 12 years. Six patients with low grade GG progressed to a higher grade, with median survival of 9.1 month after transformation. The 5 and 10 year PFS were 65 and 57%, respectively. The 5 and 10 year OS was 96 and 86% respectively. 8 of the 19 (42%) samples tested demonstrated positivity for the BRAFV600E mutation. Multivariate Cox regression analyses showed location and extent of resection were significant factors for PFS and presence of metastatsis attained significance for OS. CONCLUSION: This is the one of the largest retrospective study of pediatric GG. Identifying clinical variables, which could stratify these tumors into low- and high-risk groups might help to profile a risk-based therapeutic strategy. Collaborative multiinstitutional prospective studies are warranted to delineate treatment consensus and investigate prognostic factors.
Authors: Roy W R Dudley; Michelle R Torok; Danielle R Gallegos; Jean M Mulcahy-Levy; Lindsey M Hoffman; Arthur K Liu; Michael H Handler; Todd C Hankinson Journal: Neurosurgery Date: 2015-03 Impact factor: 4.654
Authors: So-Hyang Im; Chun Kee Chung; Byung-Kyu Cho; Kyu-Chang Wang; In-Kyu Yu; In Chan Song; Gi Jeong Cheon; Dong Soo Lee; Na-Rae Kim; Je G Chi Journal: J Neurooncol Date: 2002-09 Impact factor: 4.130
Authors: Andrew M Donson; Bette K Kleinschmidt-DeMasters; Dara L Aisner; Lynne T Bemis; Diane K Birks; Jean M Mulcahy Levy; Amy A Smith; Michael H Handler; Nicholas K Foreman; Sarah Z Rush Journal: Brain Pathol Date: 2013-12-23 Impact factor: 6.508
Authors: Laura Pastor; Sara Iglesias; Bienvenido Ros; Bernardo Weil; María Isabel Martínez-León; Miguel Ángel Arráez Journal: Childs Nerv Syst Date: 2019-07-09 Impact factor: 1.475